BREAKING: Vinay Prasad is leaving the FDA for the second time. First reported by the WSJ
www.statnews.com/2026/03/06/f...
The TrumpRx website says, prominently, "Find the world's lowest prices on prescription drugs." And then: "TrumpRx is rewriting the script, bringing major savings on essential medications for all Americans." That's difficult to square with Klomp's remarks. 1/3
www.statnews.com/2026/03/19/c...
As the New York Times has recently demonstrated, the TrumpRx prices are not the lowest in the world. www.nytimes.com/2026/03/18/w... 2/3
Excited to see this piece with @michaelannica.bsky.social and @rachelsachs.bsky.social out
We looked at the Rural Health Transformation Program: Its funding formula had a clear small-state bias; we ask whether its scoring methodology also perhaps favored red states
academic.oup.com/healthaffair...
Now up at Health Affairs Forefront, Kristi Martin and I analyze the published explanations for the 2027 cycle of the Medicare drug price negotiation program. We focus on what's in (and what's not in) the explanations, as well as implications for future cycles. www.healthaffairs.org/content/fore...
New @jama.com commentary by @rachelsachs.bsky.social @dusetzinas.bsky.social &myself on biosimilar drug competition and price declines.
jamanetwork.com/journals/jam...
The Trump administration is counting on its drug pricing efforts to help with the midterm elections.
Glad to see STAT highlight the issue of delaying overseas launches, including linking to the public comments @rgfrank.bsky.social, Kristi Martin, and I submitted to CMS on the international reference pricing models. www.statnews.com/2026/03/24/t... www.brookings.edu/articles/com...
And if, as Klomp argues, "it was never meant to be used by Americans with health insurance," the website's references to "all Americans" and "every American" are misleading at best. 3/3
Information from CMS’s published explanations of the Medicare Drug Price Negotiation Program negotiated prices for 2027 will help manufacturers and other stakeholders meaningfully engage in the negoti...
The high price of drugs continues to be the focus of policy discussions, with attention often drawn to the importance of promoting price competition through the use of generic and biosimilar versions ...